TAE684
Information
- Drug Name
- TAE684
- Description
- Entry(CIViC)
- 10
CIViC
Annotation
Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
---|---|---|---|---|---|---|
In a panel of 602 cancer cell lines, 3/134 NSCLC c... | ALK | ALK EML4-ALK E6;A20 | Sensitivity | true | CIViC Evidence | detail |
Exon-array and RT-PCR was used to screen a panel o... | ALK | ALK EML4-ALK E6;A20 | Sensitivity | false | CIViC Evidence | detail |
The L2155S mutation in ROS1 was identified in the ... | ROS1 | ROS1 CD74-ROS1 L2155S | Resitance or Non-Reponse | true | CIViC Evidence | detail |
A cell line called LM1 was established from the bo... | ALK | ALK CLTC-ALK | Sensitivity | true | CIViC Evidence | detail |
The I1171T ALK kinase domain mutaion was found in ... | ALK | ALK p.Ile1171Thr (p.I1171T) ALK p.Ile1171Thr (p.I1171T) | Sensitivity | true | CIViC Evidence | detail |
The V1180L mutation in the kinase domain of rearra... | ALK | ALK EML4-ALK V1180L | Sensitivity | true | CIViC Evidence | detail |
Treatment of Ba/F3 cells expressing EML4-ALK 1151 ... | ALK | ALK EML4-ALK T1151INST | Resitance or Non-Reponse | true | CIViC Evidence | detail |
SH-SY5Y and Kelly cells with mutant ALK (F1174L) a... | ALK |
ALK p.Phe1174Leu (p.F1174L) ( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L) ( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) |
Sensitivity | true | CIViC Evidence | detail |
TAE684 inhibits growth of Ba/F3 cells expressing A... | ALK |
ALK p.Arg1275Gln (p.R1275Q) ( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q) ( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) |
Sensitivity | true | CIViC Evidence | detail |
The SMS-KCNR cell line harboring the R1275Q mutati... | ALK |
ALK p.Arg1275Gln (p.R1275Q) ( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q) ( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |